Skip to content

Reference information only. Therapept does not sell peptides and does not provide medical advice.Research-use notice

Therapept

Growth hormone secretagogue

Hexarelin

A synthetic growth hormone-releasing hexapeptide, INN examorelin, with no FDA-approved drug product and no entry on FDA's compounding tables. It is named on the WADA Prohibited List.

UnapprovedAlso listed as: Examorelin, EP-23905, MF-6003

Why people are interested in Hexarelin

A synthetic growth hormone-releasing hexapeptide, INN examorelin, with no FDA-approved drug product and no entry on FDA's compounding tables. It is named on the WADA Prohibited List.

  • Growth hormone secretagogues— a research-category classification, not a claimed use

Where the interest comes from differs by compound: published research, an approved use, clinical discussion, community discussion and vendor claims are different things. This page keeps them apart — the sections below say which kind of source supports each statement.

Quick facts

Molecular weight
887.0 g/mol
Sequence length
40 chars
CAS number
140703-51-1
PubChem CID
6918297

0 evidence records indexed · 0 clinical trials · last reviewed 15 September 2026

Research at a glance

No evidence records in this file yet.

Open the full evidence file

What has actually been studied

    What is still unknown

    What we know

      Editorial reading of the records below, labelled as Therapept analysis. How records are built

      What remains uncertain

        Preparation and handling

        Lyophilized peptides ship as powders; whatever happens next involves diluents, concentrations and storage conditions that are compound- and product-specific. Therapept’s preparation guides explain the vocabulary and the arithmetic; the product’s own documentation states its requirements.

        What “lyophilized” meansReconstitution basicsStorage, by source kindConcentration calculator

        United States regulatory status

        No FDA-approved product

        • No approved drug product exists in Drugs@FDA.
        • Not listed on FDA's Category 2 or withdrawn-nomination compounding tables at review.
        • No registered studies were returned by ClinicalTrials.gov for the intervention name hexarelin at review.

        Anti-doping status

        Named at S2.2.4 among GH-releasing peptides, as “examorelin (hexarelin)”. Prohibited at all times.

        Regulatory status describes how a substance is classified. It is not a safety assessment, and it says nothing about the quality of any particular material.

        Technical identity

        Compound class
        Growth hormone secretagogue; synthetic hexapeptide containing 2-methyl-D-tryptophan
        Sequence
        His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2
        Molecular formula
        C47H58N12O6
        Molecular weight
        887.0 g/mol
        CAS number
        140703-51-1
        PubChem CID
        6918297
        Research categories
        Growth hormone secretagogues